BioWorld

Dec. 3, 2008

View Archived Issues

Titan, Targeted Genetics, InSite Cut Staff; Enzon Nixes Spin-off

A day after the National Bureau of Economic Research declared the last 12 months an official recession, the restructuring parade for biotech continues, as firms try to stretch their limited capital as far as possible. (BioWorld Today) Read More

XenoPort's Shares Plummet on Failed GERD Drug Trial

Read More

FDA Gives TransMolecular OK for Phase III Brain Cancer Study

Read More

NewCo News: Zacharon Pharma Targets Glycans with Small Molecules

Read More

Corrections & Clarifications

Read More

Horizon's HZT-501 Reduces GI Ulcers in Pivotal Studies in Pain

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Financings Roundup

Read More